Cosentyx snrdy 300MG dose-2PENML
Ended Awarded Last action
- Contract number
- SPE2DR26F9EEV
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3 Part of Cencora, Inc.
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $13,261
Award facts
- Contract value 100% obligated
- $13,260.96 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency (DLA) awarded a delivery order valued at $13,260.96 to Amerisourcebergen Drug Corp for COSENTYX (secukinumab) 300mg dose in 2 pens per milliliter formulation. The award, issued on February 2, 2026, with an ultimate completion date of February 3, 2026, was made on a non-set-aside, firm fixed-price basis. Performance will occur at Amerisourcebergen's facility in Conshohocken, Pennsylvania. This delivery order is issued under the company's parent organization, Cencora, Inc. (doing business as Amerisourcebergen), which holds a substantial Indefinite Delivery Contract with DLA Troop Support Medical valued at up to $999,999,999.00 through December 2031, serving as the vehicle for delivering comprehensive pharmaceutical products and medical supplies to support military healthcare programs globally.
COSENTYX is a biologic immunosuppressant medication used in the treatment of various inflammatory and autoimmune conditions, including rheumatoid arthritis, psoriasis, and psoriatic arthritis. As a critical pharmaceutical supplier to the federal government, Amerisourcebergen leverages its extensive IDC to efficiently fulfill medical procurement requirements across military treatment facilities and veteran healthcare systems. The competitive award to Amerisourcebergen reflects its established capability to meet DLA's stringent requirements for pharmaceutical distribution and its role as a key vendor within the Defense Health Agency's medical supply chain.
Quick answers
Who was awarded contract SPE2DR26F9EEV?
SPE2DR26F9EEV was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on February 2, 2026.
How much is contract SPE2DR26F9EEV worth?
The government has obligated $13,261 on SPE2DR26F9EEV.
Is contract SPE2DR26F9EEV an order under another contract?
Yes. SPE2DR26F9EEV is a delivery order under SPE2DR25D1017, an indefinite delivery contract.
Was contract SPE2DR26F9EEV competed?
The extent of competition for SPE2DR26F9EEV was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award